Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive ...
Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient ...
DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...
DexCom stock crashed after the company reported disappointing Q2 results and cut its full-year guidance. This performance raised questions about the potential impact of GLP-1 drugs on DexCom's ...
If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that price might actually represent for you. The stock has been under pressure ...
Ed Gamble and Roxy Horner, who live with Type 1 diabetes, at the Dexcom's "No Pricks Parlour" vintage ice cream truck, handing out free ice cream on London's South Bank to celebrate Diabetes Awareness ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 ...
Progress in medicine could lead to a smaller target market for DexCom. However, the company is expanding opportunities through innovation. On the other hand, DexCom has attractive opportunities that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results